Sfoglia per Autore
Deferiprone
2010-01-01 A. Piga; S. Roggero; I. Salussolia; D. Massano; M. Serra; F. Longo
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients.
2012-01-01 De Francia S; Massano D; Piccione FM; Pirro E; Racca S; Di Carlo F; Piga A.
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness
2014-01-01 Cusato, J; Allegra, S; Massano, D; De Francia, S; Piga, A; D'Avolio, A.
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children
2016-01-01 Sarah Allegra, Jessica Cusato, Silvia De Francia, Arianna Arduino, Filomena Longo, Davide Massano, Antonio Piga, Antonio D'Avolio
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes
2016-01-01 Sarah Allegra, Silvia De Francia, Jessica Cusato, Arianna Arduino, Elisa Pirro, Davide Massano, Filomena Longo, Antonio Piga, Antonio D'Avolio.
Deferasirox AUC efficacy cutoff and role of pharmacogenetics
2016-01-01 Allegra, S; Cusato, J; De Francia, S; Massano, D; Piga, A; D'Avolio, A
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment
2016-01-01 Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia
2016-01-01 Allegra, Sarah; De Francia, Silvia; Longo, Filomena; Massano, Davide; Cusato, Jessica; Arduino, Arianna; Pirro, Elisa; Piga, Antonio; D'Avolio, Antonio
Role of pharmacogenetics on deferasirox AUC and efficacy
2016-01-01 Cusato, Jessica; Allegra, Sarah; DE FRANCIA, Silvia; Massano, Davide; Piga, Antonio Giulio; D'Avolio, Antonio
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients
2017-01-01 Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients
2017-01-01 Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Arduino, Arianna; Massano, Davide; Longo, Filomena; Piga, Antonio; D'Avolio, Antonio
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children
2018-01-01 Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio
Clinical relevance of deferasirox trough levels in β-thalassemia patients
2018-01-01 Allegra, Sarah; Massano, Davide; De Francia, Silvia; Longo, Filomena; Piccione, Francesca; Pirro, Elisa; Cusato, Jessica; D'Avolio, Antonio; Piga, Antonio
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients
2018-01-01 Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes
2018-01-01 Allegra, Sarah; Cusato, Jessica; DE FRANCIA, Silvia; Arduino, A; Longo, Filomena; Pirro, Elisa; Massano, Davide; DE NICOLO', Amedeo; Piga, Antonio Giulio; D'Avolio, Antonio
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients
2019-01-01 Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
Deferiprone | 2010 | A. Piga; S. Roggero; I. Salussolia; D. Massano; M. Serra; F. Longo | |
A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. | 2012 | De Francia S; Massano D; Piccione FM; Pirro E; Racca S; Di Carlo F; Piga A. | |
Influence of single-nucleotide polymorphisms on deferasirox C-trough levels and effectiveness | 2014 | Cusato, J; Allegra, S; Massano, D; De Francia, S; Piga, A; D'Avolio, A. | |
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children | 2016 | Sarah Allegra, Jessica Cusato, Silvia De Francia, Arianna Arduino, Filomena Longo, Davide Massano, Antonio Piga, Antonio D'Avolio | |
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes | 2016 | Sarah Allegra, Silvia De Francia, Jessica Cusato, Arianna Arduino, Elisa Pirro, Davide Massano, Filomena Longo, Antonio Piga, Antonio D'Avolio. | |
Deferasirox AUC efficacy cutoff and role of pharmacogenetics | 2016 | Allegra, S; Cusato, J; De Francia, S; Massano, D; Piga, A; D'Avolio, A | |
Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment | 2016 | Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio | |
Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia | 2016 | Allegra, Sarah; De Francia, Silvia; Longo, Filomena; Massano, Davide; Cusato, Jessica; Arduino, Arianna; Pirro, Elisa; Piga, Antonio; D'Avolio, Antonio | |
Role of pharmacogenetics on deferasirox AUC and efficacy | 2016 | Cusato, Jessica; Allegra, Sarah; DE FRANCIA, Silvia; Massano, Davide; Piga, Antonio Giulio; D'Avolio, Antonio | |
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients | 2017 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio | |
Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients | 2017 | Allegra, Sarah; De Francia, Silvia; Cusato, Jessica; Arduino, Arianna; Massano, Davide; Longo, Filomena; Piga, Antonio; D'Avolio, Antonio | |
Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children | 2018 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Piga, Antonio; D'Avolio, Antonio | |
Clinical relevance of deferasirox trough levels in β-thalassemia patients | 2018 | Allegra, Sarah; Massano, Davide; De Francia, Silvia; Longo, Filomena; Piccione, Francesca; Pirro, Elisa; Cusato, Jessica; D'Avolio, Antonio; Piga, Antonio | |
Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients | 2018 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio | |
Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes | 2018 | Allegra, Sarah; Cusato, Jessica; DE FRANCIA, Silvia; Arduino, A; Longo, Filomena; Pirro, Elisa; Massano, Davide; DE NICOLO', Amedeo; Piga, Antonio Giulio; D'Avolio, Antonio | |
The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients | 2019 | Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; Longo, Filomena; Pirro, Elisa; Massano, Davide; Avataneo, Valeria; De Nicolò, Amedeo; Piga, Antonio; D'Avolio, Antonio |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile